Sustainable Insight Capital Management LLC Makes New $531,000 Investment in Merck & Co., Inc. $MRK

Sustainable Insight Capital Management LLC purchased a new stake in Merck & Co., Inc. (NYSE:MRK) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,412 shares of the company’s stock, valued at approximately $531,000.

Several other large investors have also recently modified their holdings of the business. Kingdom Financial Group LLC. bought a new stake in shares of Merck & Co., Inc. in the fourth quarter worth $25,000. Abound Financial LLC acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at $26,000. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. during the 4th quarter worth $26,000. High Note Wealth LLC raised its position in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. during the 4th quarter worth $31,000. Institutional investors own 76.07% of the company’s stock.

Analysts Set New Price Targets

MRK has been the topic of a number of analyst reports. Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. JPMorgan Chase & Co. raised their price objective on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Morgan Stanley lifted their price objective on Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. Bank of America upped their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Finally, Guggenheim increased their target price on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average target price of $133.94.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced initial access plans for alimatravir, its investigational once-monthly oral HIV PrEP in Phase 3 development, and said it has signed voluntary licensing agreements covering 129 countries. That broad access strategy could support adoption in large international markets if the drug is approved. Article Title
• Neutral Sentiment: Merck also issued a company release on the same alimatravir access plan, reinforcing that the program is moving forward and that it is trying to expand availability in regions that account for most new HIV diagnoses globally. Article Title
• Neutral Sentiment: Traders also bought a high volume of Merck call options, which may reflect rising bullish speculation around the stock and the HIV pipeline, but it does not by itself change fundamentals. Article Title
• Negative Sentiment: Par Health launched the first generic version of Janumet XR in the U.S., which may pressure Merck’s diabetes-related sales and adds another competitive headwind for an established product. Article Title

Merck & Co., Inc. Price Performance

MRK stock opened at $131.06 on Friday. The firm has a market cap of $323.68 billion, a price-to-earnings ratio of 36.92, a PEG ratio of 5.18 and a beta of 0.19. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $131.74. The company’s fifty day simple moving average is $121.67 and its 200 day simple moving average is $117.71.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter in the prior year, the firm posted $2.22 earnings per share. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts expect that Merck & Co., Inc. will post 2.74 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were given a dividend of $0.85 per share. The ex-dividend date was Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. Merck & Co., Inc.’s dividend payout ratio is presently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.